Clinical trials: Gastric Acid Secretory Disorders
Pulmonary Disease, Chronic Obstructive
A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced
This is a Phase I study to assess the combined effects of food and suppression of gastric acid secretion on the relative bioavailability of an immediate release (IR) tablet formulation and prototype bioenhanced formulations of…
- Trial name
- NCT01453478
- Testing
- GSK1325756
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Severe Obesity
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
The purpose of this study is to examine the efffects of bile acid and bile acids sequestrants on GLP-1 secretion, in patients after Roux-en-Y gastric bypass.
- Trial name
- NCT02952963
- Testing
- Chenodeoxycholic Acid, Colesevelam
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Hvidovre University Hospital
Condition Measuring Alkaline Tide and Filling Symptoms' Questionnaire After Abrupt or Gradual Step Down Cessation of PPI
Gastric Acid Rebound Secretion Measured by Alkaline Tide
Gastro esophageal reflux disease and ulcer related or non-ulcer dyspepsia, attacks 20% of the Western population. These millions of patients are treated continuously with PPI for different periods, many for many years.
- Trial name
- NCT01315444
- Testing
- Stop PPI gradually
- Sponsor
- Rabin Medical Center
Pulmonary Disease, Chronic Obstructive
GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects
This 2-part study will be carried out on healthy elderly subjects to evaluate relative bioavailability of danirixin formulations.
- Trial name
- NCT03457727
- Testing
- Danirixin, Omeprazole
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gastroesophageal Reflux Disease
Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD
The purpose of the study is to compare the effect of two different drugs, rabeprazole (20 mg) and pantoprazole (40 mg), and their effects on the amount of acid produced by your stomach on evening and at night after standard…
- Trial name
- NCT00304421
- Testing
- rabeprazole, pantoprazole
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Islet Cell Adenoma, Neoplasm Metastasis
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors.
- Conditions
- Islet Cell Adenoma, Neoplasm Metastasis, Zollinger Ellison Syndrome
- Trial name
- NCT00001165
- Testing
- combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Zollinger Ellison Syndrome
Treatment of Zollinger-Ellison Syndrome
In patients with Zollinger-Ellison Syndrome the level of gastric acid is elevated. This increased level of gastric acid is what causes the symptoms of the disease.
- Trial name
- NCT00001241
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Achlorhydria, Gastrinoma
Evaluating Patients With Abnormal Levels of Gastric Acid
This study is used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities in the secretion of gastric acid.
- Conditions
- Achlorhydria, Gastrinoma, Zollinger Ellison Syndrome
- Trial name
- NCT00001240
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Zollinger-Ellison Syndrome
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.
- Trial name
- NCT00079833
- Testing
- Esomeprazole magnesium (Nexium)
- Where
- 8 sites in United States, France
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Severe Obesity
Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
The purpose of this study is to examine the effects of bile acid and bile acids sequestrants on GLP-1 Secretion, during a meal, in patients after Roux-en-Y gastric bypass.
- Trial name
- NCT02876484
- Testing
- Colesevelam, Chenodeoxycholic Acid, Water
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Hvidovre University Hospital
Obesity
Effects of Roux-en-Y Gastric Bypass on Gastro-intestinal Hormone Secretion and Brain Responses Food Pictures
This is a cross-sectional study enrolling 11 weight-stable, formerly obese female patients 1-5 years after Roux-en-Y gastric Bypass (RYGB) 11 age- and weight-matched female subjects 10 normal weight (Body Mass Index 19-25 kg/m2)…
- Trial name
- NCT02160379
- Testing
- standard test meal
- Where
- Switzerland
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Lausanne
Esophagitis, Reflux
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
The purpose of this study was to compare the pharmacodynamics of intravenous (IV) lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive esophagitis.
- Trial name
- NCT00175045
- Testing
- Lansoprazole
- Volunteers
- 68 people
- Sponsor
- Takeda
Diabetes Mellitus
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.
- Trial name
- NCT02231658
- Testing
- Liraglutide, Lixisenatide
- Where
- 2 sites in Germany
- Volunteers
- 109 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Coronary Artery Disease, Gastroesophageal Reflux Disease
GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy
The dual antiplatelet therapy based on aspirin plays an important role in the treatment of patients with coronary heart disease.
- Trial name
- SECURE (NCT04129008)
- Testing
- Indobufen and aspirin mimetic, Aspirin and indobufen mimetic
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Beijing Anzhen Hospital
Gastric Acid Secretory Disorders
A New Method for Determining Gastric Acid Output Using a Wireless Capsule
Background: Acid-related gastrointestinal disorders are numerous and may require chronic treatment and maintenance, but they are often difficult to diagnose and treat.
- Trial name
- NCT00702533
- Testing
- Pentagastrin Injection BP, Pentagastrin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Severe Obesity
Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass
The purpose of this study is to examine the effects of bile acids on GLP-1 secretion after Roux-en-Y gastric bypass.
- Trial name
- NCT02340247
- Testing
- Water, Ursodeoxycholic Acid, Chenodeoxycholic Acid
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- Hvidovre University Hospital
Pulmonary Disease, Chronic Obstructive
A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole
The current study will help to increase our understanding of the pharmacokinetics (PK) of danirixin. The primary objective of the study is to estimate the relative bioavailability of danirixin Hydrobromide (HBr) tablet, when…
- Trial name
- NCT02453022
- Testing
- Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline